Intra-Cellular Therapies Inc. diskutieren
Intra-Cellular Therapies Inc.
WKN: A1XDTL / Symbol: ITCI / Name: ITI / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
66,00 €
-0,76 %
Buy Intra-Cellular Therapies Inc.
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target lowered by analysts at Royal Bank of Canada from $75.00 to $71.00. They now have an "outperform" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target lowered by analysts at JPMorgan Chase & Co. from $59.00 to $58.00. They now have an "overweight" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Cantor Fitzgerald from $83.00 to $87.00. They now have an "overweight" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Bank of America Co. from $62.00 to $63.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $73.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Royal Bank of Canada from $78.00 to $79.00. They now have an "outperform" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $80.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Cantor Fitzgerald from $98.00 to $101.00. They now have an "overweight" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target lowered by analysts at Royal Bank of Canada from $77.00 to $76.00. They now have an "outperform" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is now covered by analysts at TD Cowen. They set an "outperform" rating and a $75.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $101.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Bank of America Co. from $74.00 to $82.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $83.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Mizuho from $76.00 to $82.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Needham & Company LLC from $72.00 to $82.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Neueste Beiträge
Macquarie in Brookdale Sr Lvg diskutieren